Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
50 hedge funds and large institutions have $48.8M invested in Viracta Therapeutics, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 14 increasing their positions, 8 reducing their positions, and 2 closing their positions.
550% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 2
345% more call options, than puts
Call options by funds: $689K | Put options by funds: $155K
75% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 8
28% more funds holding
Funds holding: 39 → 50 (+11)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
27% less capital invested
Capital invested by funds: $67.2M → $48.8M (-$18.4M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$3.92M |
| 2 |
Goldman Sachs
New York
|
+$795K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$752K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$662K |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
+$490K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.06M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$2.01M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
-$1.76M |
| 4 |
VC
Vivo Capital
Palo Alto,
California
|
-$1.49M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$906K |
VIRX Hedge Fund Activity: Q1 2018 in Review
50 of the 4,373 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q1 2018, worth a combined $48.8M — down 27% from $67.2M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new VIRX positions and 2 closed out — a net gain of 11 holders — while 14 added to existing stakes and 8 trimmed.
The largest buyer was Boxer Capital, adding an estimated $3.92M. The largest seller was RA Capital Management, cutting an estimated $3.06M.
- 50 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q1 2018, up from 39 in Q4 2017.
- Funds reported $48.8M of Viracta Therapeutics, Inc. Common Stock stock for Q1 2018, down 27% quarter-over-quarter.
- 13 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q1 2018 and 2 closed out, a net change of +11 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q1 2018 was Boxer Capital, an estimated $3.92M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q1 2018 was RA Capital Management, an estimated $3.06M sold.
Based on aggregated 13F filings for Q1 2018.